A multicenter, randomized, double-blind, Phase II/III study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab as first-line treatment in patients with recurrent or metastatic PD-L1–positive head and neck squamous cell carcinoma (HNSCC)
Phase: Phase II-III clinical trials
Principal Investigator: Professoressa Associata Licitra Lisa Francesca Linda
Main Facility: Oncologia Medica 3 - Tumori testa-collo
Drug: Ficerafusp alfa (BCA101)
Pathologies: Head and neck cancers
ClinicalTrials.gov: Leggi i dettagli su Clinical trials
The study is designed to evaluate the efficacy and safety of ficerafusp alfa (BCA101) in combination with pembrolizumab compared with placebo plus pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) expressing PD-L1.
Ficerafusp alfa (BCA101) is a bifunctional fusion protein that:
- combines inhibition of TGF-β with blockade of the EGFR receptor;
- reduces immunosuppression within the tumor microenvironment;
- enhances the antitumor activity of immunotherapy.
Pembrolizumab is an anti–PD-1 monoclonal antibody that restores antitumor immune response and is currently the standard first-line therapy for patients with PD-L1–positive HNSCC.
The study aims to evaluate whether the combination of ficerafusp alfa and pembrolizumab can improve tumor response, progression-free survival, overall survival, and quality of life compared with standard treatment alone.
Patient enrollment is subject to verification of eligibility criteria, including:
- histologically confirmed head and neck squamous cell carcinoma;
- recurrent or metastatic disease not previously treated in the advanced setting;
- PD-L1 expression (CPS ≥1);
- adequate organ function.
Treatment assignment is performed through computerized randomization in a double-blind manner into the following arms:
- Arm A: ficerafusp alfa 1500 mg once weekly (QW) + pembrolizumab 200 mg every three weeks (Q3W)
- Arm B: ficerafusp alfa 750 mg once weekly (QW) + pembrolizumab 200 mg every three weeks (Q3W)
- Arm C (control): placebo once weekly (QW) + pembrolizumab 200 mg every three weeks (Q3W)
Treatment is administered intravenously:
- ficerafusp alfa: once weekly
- pembrolizumab: every three weeks
Treatment will continue until disease progression, unacceptable toxicity, or withdrawal by the patient or investigator.
During the study, patients will be monitored for potential adverse events, including in particular: dermatologic reactions, hematologic abnormalities, inflammatory or immune-mediated events or infusion-related reactions.
Treatment may be interrupted or modified in the event of clinically significant toxicity.
The study staff remains available for further information
(email: amo@istitutotumori.mi.it).
Last update: 21/04/2026